Related Experiment Videos
Hyperlipidemia in acute lymphoblastic leukemia.
Annals of Clinical and Laboratory Science
|March 1, 1984
Summary
This study found that abnormal triglyceride composition in very low-density lipoproteins (VLDL) may cause hyperlipidemia in leukemia. This abnormal composition appears to be a late-stage feature of the condition.
Area of Science:
- Biochemistry
- Hematology
- Lipid Metabolism
Background:
- Investigating the link between Type V hyperlipidemia and advanced lymphoblastic Leukemia (ALL).
- Examining potential mechanisms for hyperlipidemia in leukemia patients.
- Previous reports suggested antibodies or heparin involvement, which were not detected here.
Observation:
- Lipemic serum from a patient with Type V hyperlipidemia and ALL was analyzed.
- Fatty acid analysis revealed a high proportion of stearic acid (18:0) in triglyceride esters.
- Very low-density lipoproteins (VLDL) showed slower in vitro degradation by lipoprotein lipase (LPL).
Findings:
- Abnormal triglyceride composition, specifically high stearic acid, hinders VLDL degradation by LPL.
- This suggests a mechanism where altered VLDL substrate quality contributes to hyperlipidemia in leukemia.
- Nine other ALL cases showed hypertriglyceridemia with altered ApoB/ApoA-I but normal triglyceride composition, indicating compositional changes are a later feature.
Implications:
- Abnormal triglyceride composition is a potential cause of hyperlipidemia in leukemia.
- This specific lipid abnormality may develop later in the course of leukemia.
- Understanding these mechanisms could inform the management of hyperlipidemia in cancer patients.